©2014 Baishideng Publishing Group Inc.
World J Hepatol. May 27, 2014; 6(5): 315-325
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.315
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.315
Table 3 Prophylactic schemes against hepatitis B virus recurrence after liver and renal transplantation when grafts are from hepatitis B virus positive donors
| Donor | Recipient | Prophylaxis | |
| Liver transplantation | Anti-HBc positive | HBsAg positive | HBIG plus NA |
| HBsAg negative | No prophylaxis | ||
| Anti-HBc positive | |||
| Anti-HBs positive | |||
| Anti-HBc negative | Long term lamivudine | ||
| Anti-HBs negative | |||
| HBsAg positive | Anti-HBc positive | HBIG plus NA | |
| Kidney transplantation | Anti-HBc positive | HBsAg negative | No prophylaxis |
| Treatment when HBV DNA increases | |||
| HBsAg positive | HBsAg positive | HBIG plus lamivudine | |
| (HBV DNA negative) | HBsAg negative | Long term lamivudine | |
| (HBV DNA) negative |
- Citation: Pipili C, Cholongitas E. Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation. World J Hepatol 2014; 6(5): 315-325
- URL: https://www.wjgnet.com/1948-5182/full/v6/i5/315.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i5.315